This invention relates to novel 5- [(hydroxymethyl)aryl] -substituted pyrrolo[2, 1- ] [1, 2, 4] triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.